We suggest that low UCP-2 levels are pivotal to maintain the adaptive phase of cardiac hypertrophy in the concomitant presence of hypertension, whereas an increased expression of UCP-2 reduces the ability of cardiomyocytes to uptake glucose in a situation where they have lost their metabolic flexibility. Here, UCP2 is linked to cardiac hypertrophy.